Rinvoq ER 15 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FFL9S
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $80,918
Award facts
- Contract value 100% obligated
- $80,917.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $80,917.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 30, 2026, for the supply of RINVOQ ER 15 mg tablets (30-count units). This non-set-aside competitive award is scheduled for completion by February 2, 2026, with performance to take place at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at up to $999,999,999.00 through December 31, 2031.
RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, representing a specialty pharmaceutical requirement within the federal military healthcare supply chain. This delivery order exemplifies the routine pharmaceutical procurement activities conducted through DLA's established prime vendor relationships, enabling efficient fulfillment of military treatment facility and veterans' healthcare program medication needs. AmerisourceBergen's role as a major pharmaceutical distributor positions it as a critical vendor for federal medical supply chain operations, particularly in delivering brand-name specialty medications and therapeutics to support Department of Defense healthcare requirements.
Quick answers
Who was awarded contract SPE2DR26FFL9S?
SPE2DR26FFL9S was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FFL9S worth?
The government has obligated $80,918 on SPE2DR26FFL9S.
Is contract SPE2DR26FFL9S an order under another contract?
Yes. SPE2DR26FFL9S is a delivery order under SPE2DR25D1109, an indefinite delivery contract.
Was contract SPE2DR26FFL9S competed?
The extent of competition for SPE2DR26FFL9S was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award